Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma

Foresight Diagnostics and QIAGEN have announced a global strategic partnership to develop and commercialize a kit-based version of Foresight’s CLARITY™ assay. This collaboration aims to enable in vitro diagnostic (IVD) and companion diagnostic (CDx) applications for lymphoma and other hematological malignancies. The goal is to create a standardized, regulated diagnostic kit that, once validated and approved in pharmaceutical-sponsored trials, would be the only circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) assay available as both a central laboratory service and a diagnostic kit. This advancement is expected to support clinical decision-making and therapeutic strategies for patients with hematological cancers.